Amphista Therapeutics

CAMBRIDGE, UK, June 8, 2026 Amphista Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the...

CAMBRIDGE, UK, April 24, 2026 Amphista Therapeutics has unveiled new preclinical data demonstrating the therapeutic potential of its SMARCA2...